Home LiteratureArticle Details
PMID: 16047143 Published · ppublish English Journal Article Review

Role of immature myeloid cells in mechanisms of immune evasion in cancer.

Cancer immunology, immunotherapy : CII ·Vol. 55 ·No. 3 ·2006-03-00 ·Pages 237-45

Kusmartsev S, Gabrilovich DI

Abstract

Tumor affects myelopoiesis by inhibiting the process of differentiation/maturation of antigen-presenting cells from their myeloid precursors and by stimulating an accumulation of immature myeloid cells in cancer patients and tumor-bearing mice. These immature myeloid cells can contribute greatly to tumor progression and promote tumor evasion from immune attack: i) by inhibiting development of adaptive immune responses against tumor in lymphoid organs; ii) by migrating into tumor site and differentiating there into highly immune suppressive tumor-associated macrophages. Immature myeloid cells and tumor-associated macrophages utilize different JAK/STAT signaling pathways and different mechanisms to control T cell responses, which include increased production of TGF-beta, reactive oxygen species, peroxynitrites, as well as enhanced L-arginine metabolism. Understanding of precise mechanisms, which tumors use to affect differentiation of APC from myeloid cell precursors and inhibit T cell responses, could help to develop new approaches for cancer therapy and substantially improve efficiency of existing cancer vaccination strategies.

MeSH Terms
Animals Antigen-Presenting Cells/cytology,immunology Cell Differentiation Humans Immune Tolerance/immunology Myeloid Cells/cytology,immunology Neoplasms/immunology Tumor Escape/immunology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Kusmartsev Sergei
H. Lee Moffitt Cancer Center and Research Institute and The Department of Interdisciplinary Oncology, University of South Florida, MRC 2067, 12902 Magnolia Dr, Tampa, FL 33612, USA.
Gabrilovich Dmitry I
References (64)
64 references, click to expand
  1. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide.
    J Immunol. 2001 Nov 15;167(10):5583-93 PMID: 11698429
  2. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.
    J Exp Med. 2005 Apr 18;201(8):1257-68 PMID: 15824085
  3. Stat proteins and oncogenesis.
    J Clin Invest. 2002 May;109(9):1139-42 PMID: 11994401
  4. Regulation of T cell receptor CD3zeta chain expression by L-arginine.
    J Biol Chem. 2002 Jun 14;277(24):21123-9 PMID: 11950832
  5. H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors.
    J Leukoc Biol. 2002 Aug;72(2):285-96 PMID: 12149419
  6. Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis.
    Leukemia. 2002 Sep;16(9):1763-72 PMID: 12200692
  7. Resection of solid tumors reverses T cell defects and restores protective immunity.
    J Immunol. 2000 Feb 15;164(4):2214-20 PMID: 10657677
  8. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy.
    J Immunother. 2000 Jan;23(1):115-24 PMID: 10687144
  9. Clinical significance of defective dendritic cell differentiation in cancer.
    Clin Cancer Res. 2000 May;6(5):1755-66 PMID: 10815894
  10. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells.
    Blood. 2000 Jun 1;95(11):3349-56 PMID: 10828015
  11. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation.
    J Immunol. 2000 Jul 15;165(2):779-85 PMID: 10878351
  12. CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer.
    Ann Otol Rhinol Laryngol. 2000 Aug;109(8 Pt 1):749-54 PMID: 10961808
  13. Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma.
    J Immunol. 2000 Dec 1;165(11):6056-66 PMID: 11086037
  14. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
    Blood. 2000 Dec 1;96(12):3838-46 PMID: 11090068
  15. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
    J Immunol. 2001 Jan 1;166(1):678-89 PMID: 11123353
  16. Inflammation and cancer: back to Virchow?
    Lancet. 2001 Feb 17;357(9255):539-45 PMID: 11229684
  17. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.
    Cancer Res. 2001 Apr 1;61(7):3096-104 PMID: 11306493
  18. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.
    J Immunol. 2001 May 1;166(9):5398-406 PMID: 11313376
  19. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
    Nature. 2001 Apr 26;410(6832):1107-11 PMID: 11323675
  20. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism.
    J Immunol. 2001 Jun 1;166(11):6608-15 PMID: 11359814
  21. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
    Cancer Res. 2001 Jun 15;61(12):4756-60 PMID: 11406548
  22. Reactive oxygen species as intracellular messengers during cell growth and differentiation.
    Cell Physiol Biochem. 2001;11(4):173-86 PMID: 11509825
  23. A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism.
    J Immunol. 2001 Oct 15;167(8):4293-302 PMID: 11591752
  24. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis.
    J Immunol. 2002 Sep 15;169(6):3180-90 PMID: 12218136
  25. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
    Trends Immunol. 2002 Nov;23(11):549-55 PMID: 12401408
  26. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
    J Immunol. 2002 Nov 15;169(10):5796-804 PMID: 12421960
  27. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
    J Immunol. 2003 Jan 1;170(1):270-8 PMID: 12496409
  28. C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum.
    Eur J Immunol. 2003 Jan;33(1):19-28 PMID: 12594828
  29. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells.
    J Immunol. 2003 May 15;170(10):5064-74 PMID: 12734351
  30. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.
    J Immunol. 2003 Aug 1;171(3):1232-9 PMID: 12874210
  31. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species.
    J Leukoc Biol. 2003 Aug;74(2):186-96 PMID: 12885935
  32. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.
    Cancer Res. 2003 Aug 1;63(15):4441-9 PMID: 12907617
  33. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.
    Blood. 2003 Sep 15;102(6):2138-45 PMID: 12750171
  34. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
    J Immunol. 2004 Jan 15;172(2):989-99 PMID: 14707072
  35. Tumour-educated macrophages promote tumour progression and metastasis.
    Nat Rev Cancer. 2004 Jan;4(1):71-8 PMID: 14708027
  36. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity.
    Cancer Res. 2004 Feb 1;64(3):1130-9 PMID: 14871848
  37. Tumor skewing of CD34+ progenitor cell differentiation into endothelial cells.
    Int J Cancer. 2004 Apr 20;109(4):516-24 PMID: 14991572
  38. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.
    Cancer Immunol Immunother. 2004 May;53(5):422-30 PMID: 14648070
  39. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
    Cancer Res. 2004 Aug 15;64(16):5839-49 PMID: 15313928
  40. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice.
    J Nutr. 2004 Oct;134(10):2653-9 PMID: 15465762
  41. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.
    Cancer Cell. 2004 Oct;6(4):409-21 PMID: 15488763
  42. Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice.
    Int J Cancer. 1989 Aug 15;44(2):307-14 PMID: 2527208
  43. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells.
    J Immunol. 1991 Jul 1;147(1):22-8 PMID: 1711076
  44. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review).
    Free Radic Res Commun. 1992;17(4):221-37 PMID: 1473734
  45. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.
    Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6254-8 PMID: 7603979
  46. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence.
    Cancer Immunol Immunother. 1995 Jul;41(1):37-45 PMID: 7641218
  47. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide.
    J Immunol. 1996 Mar 1;156(5):1916-22 PMID: 8596044
  48. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses.
    Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13119-24 PMID: 8917554
  49. Arginine metabolism: nitric oxide and beyond.
    Biochem J. 1998 Nov 15;336 ( Pt 1):1-17 PMID: 9806879
  50. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
    J Immunol. 1998 Nov 15;161(10):5313-20 PMID: 9820504
  51. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.
    Blood. 1998 Dec 1;92(11):4150-66 PMID: 9834220
  52. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.
    J Immunol. 1999 May 15;162(10):5728-37 PMID: 10229805
  53. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers.
    Int J Immunopharmacol. 1999 Apr;21(4):241-52 PMID: 10408632
  54. Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization.
    Cell Mol Life Sci. 1999 Jul;55(8-9):1015-28 PMID: 10484661
  55. Mechanisms and functional significance of tumour-induced dendritic-cell defects.
    Nat Rev Immunol. 2004 Dec;4(12):941-52 PMID: 15573129
  56. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
    J Immunol. 2005 Jan 15;174(2):636-45 PMID: 15634881
  57. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.
    Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90 PMID: 15753302
  58. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.
    J Immunol. 2005 Apr 15;174(8):4880-91 PMID: 15814715
  59. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
    Cancer Res. 2005 Apr 15;65(8):3044-8 PMID: 15833831
  60. Tumor-induced immune dysfunctions caused by myeloid suppressor cells.
    J Immunother. 2001 Nov-Dec;24(6):431-46 PMID: 11759067
  61. A critical role for Stat3 signaling in immune tolerance.
    Immunity. 2003 Sep;19(3):425-36 PMID: 14499117
  62. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  63. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.
    J Immunol. 2004 Jan 1;172(1):464-74 PMID: 14688356
  64. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.
    Nat Med. 2004 Jan;10(1):48-54 PMID: 14702634
Article Info
Journal
Cancer immunology, immunotherapy : CII
Abbr.
Cancer Immunol Immunother
ISSN
0340-7004
Published
2006-03-00
Epub
2005-00-27
Pages
237-45
Language
English
Region
Germany
NLM ID
8605732
PMCID
PMC1350971
Subset
IM
Grants
NCI NIH HHS · R01 CA084488 · United States
NCI NIH HHS · R01 CA100062 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com